Tharimmune Receives EMA Feedback On TH104 Clinical Program, Including Guidance On Planned Phase 2 Trial; The Agency Found The Design And Main Features Of The Proposed Phase 2 Study Overall Acceptable With Some Comments, Also Provided General Guidance For Design Of Future Phase 3 Study
Portfolio Pulse from Benzinga Newsdesk
Tharimmune has received feedback from the European Medicines Agency (EMA) on its TH104 clinical program. The EMA found the design of the proposed Phase 2 study acceptable with some comments and provided guidance for a future Phase 3 study.
October 30, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune received positive feedback from the EMA on its TH104 clinical program, with the Phase 2 study design deemed acceptable and guidance provided for Phase 3.
The EMA's feedback is a positive regulatory development for Tharimmune, as it indicates that the Phase 2 study design is largely acceptable. This can boost investor confidence and potentially lead to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90